Abstract
Cancer immunotherapy is a validated and critically important approach for treating patients with cancer. Given the vast research and clinical investigation efforts dedicated to advancing both endogenous and synthetic immunotherapy approaches, there is a need to focus on crucial questions and define roadblocks to the basic understanding and clinical progress. Here, we define ten key challenges facing cancer immunotherapy, which range from lack of confidence in translating pre-clinical findings to identifying optimal combinations of immune-based therapies for any given patient. Addressing these challenges will require the combined efforts of basic researchers and clinicians, and the focusing of resources to accelerate understanding of the complex interactions between cancer and the immune system and the development of improved treatment options for patients with cancer.
Keywords
ImmunotherapyCancer immunotherapyCancerCancer treatmentClinical trialIntensive care medicineBiologyMedicineBioinformaticsInternal medicine
MeSH Terms
HumansImmunotherapyModelsBiologicalNeoplasmsTumor Microenvironment
Affiliated Institutions
Related Publications
Advances in immunotherapy for hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated by the immune system. Systemic therapy is used in the advanced stage and until 2017 co...
Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
Abstract The aim of T-cell–based immune therapy for cancer has been to generate durable clinical benefit for patients. Following a generation of therapies that largely showed mi...
Delivery technologies for cancer immunotherapy
Immunotherapy has become a powerful clinical strategy for treating cancer. The number of immunotherapy drug approvals has been increasing, with numerous treatments in clinical a...
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
Abstract Ovarian cancer is the second most common cause of gynecologic cancer death in women around the world. The outcomes are complicated, because the disease is often diagnos...
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
These findings define a genetic basis for benefit from CTLA-4 blockade in melanoma and provide a rationale for examining exomes of patients for whom anti-CTLA-4 agents are being...
Publication Info
- Year
- 2020
- Type
- review
- Volume
- 52
- Issue
- 1
- Pages
- 17-35
- Citations
- 2118
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
2118
OpenAlex
40
Influential
1696
CrossRef
Cite This
Priti S. Hegde,
Daniel S. Chen
(2020).
Top 10 Challenges in Cancer Immunotherapy.
Immunity
, 52
(1)
, 17-35.
https://doi.org/10.1016/j.immuni.2019.12.011
Identifiers
- DOI
- 10.1016/j.immuni.2019.12.011
- PMID
- 31940268